Table 3.
Comparative analysis of patients with autoimmune hepatitis concomitant with nonalcoholic fatty liver disease and patients with nonalcoholic fatty liver disease with autoimmune phenomena
|
Variable
|
Patients with AIH concomitant with NAFLD (n = 61)
|
Patients with NAFLD with autoimmune phenomena (n = 34)
|
P
value
|
| Age, yr | 52.05 ± 11.11 | 43.68 ± 13.71 | < 0.001 |
| Male sex, n (%) | 13 (21.3) | 6 (17.6) | |
| BMI, kg/m2 | 24.21 ± 3.10 | 24.65 ± 2.02 | |
| Laboratory | |||
| AST, U/L | 55.03 ± 47.31 | 50.03 ± 29.26 | |
| ALT, U/L | 66.62 ± 74.94 | 86.01 ± 62.59 | |
| AKP, U/L | 63.00 (45.00, 84.00) | 75.00 (54.00, 87.00) | |
| GGT, U/L | 49.27 ± 32.24 | 69.26 ± 44.07 | < 0.05 |
| Total bilirubin, mg/dL | 10.20 (8.60, 14.10) | 10.25 (7.40, 13.67) | |
| Direct bilirubin, mg/dL | 4.20 (3.20, 5.00) | 3.70 (2.92, 4.65) | |
| IgG | 15.60 ± 4.57 | 13.81 ± 2.67 | < 0.05 |
| IgM | 1.18 ± 0.45 | 1.28 ± 0.57 | |
| Histological steatosis stage, n (%) | |||
| S1 | 39 (63.9) | 8 (23.5) | |
| S2 | 17 (27.9) | 10 (29.4) | |
| S3 | 5 (8.2) | 16 (47.1) | |
| Histological fibrosis stage, n (%) | |||
| F1 | 17 (27.9) | 6 (17.6) | |
| F2 | 22 (36.1) | 14 (41.2) | |
| F3 | 16 (26.2) | 11 (32.4) | |
| F4 | 6 (9.8) | 3 (8.8) | |
| CAP, dB/m | 272.57 ± 44.39 | 293.41 ± 51.04 | < 0.05 |
| LSM in total, kPa | 9.34 ± 7.14 | 6.49 ± 2.44 | < 0.05 |
| In steatosis S1 | 9.19 ± 8.11 | 5.28 ± 1.88 | < 0.05 |
| In steatosis S2 | 7.80 ± 3.47 | 6.31 ± 2.18 | |
| In steatosis S3 | 15.76 ± 6.25 | 7.20 ± 2.69 | < 0.01 |
Distributions are expressed as the mean ± SD or median [interquartile range] or number (percentage). AKP: Alkaline phosphatase; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; BMI: Body mass index; CAP: Controlled attenuation parameter; GGT: Gamma-glutamyl transferase; LSM: Liver stiffness measurement; AIH: Autoimmune hepatitis; NAFLD: Nonalcoholic fatty liver.